Scientific deep-dive
Peptides to Preserve Muscle on GLP-1: What the Evidence Shows
No human RCT shows sermorelin, ipamorelin, CJC-1295, BPC-157, or tesamorelin preserves muscle during GLP-1 therapy. A review of each peptide best human data vs the resistance-training and protein evidence that works.
About a quarter of the weight lost on a GLP-1 drug like semaglutide (Wegovy) or tirzepatide (Zepbound) is lean mass — a mix of skeletal muscle, water, and supporting tissue [3]. That number worries anyone who has worked hard to build strength, and the wellness industry has a ready answer: peptides. Sermorelin, ipamorelin, CJC-1295, BPC-157, and tesamorelin are all marketed, in various combinations, as tools to “preserve muscle” during GLP-1-driven weight loss. This article evaluates what the human evidence actually shows — and the honest answer is that none of these peptides has been tested in a human clinical trial for muscle preservation during GLP-1 therapy. The evidence-based levers are resistance training and adequate dietary protein, and that fact is not a footnote.
Why GLP-1s cause lean-mass loss in the first place
GLP-1 receptor agonists suppress appetite profoundly, which is how they work. SURMOUNT-1 (Jastreboff 2022 [1]) randomized 2,539 adults with obesity to tirzepatide or placebo for 72 weeks; the 15 mg arm lost a mean of −20.9% total body weight versus −3.1% on placebo. STEP-1 (Wilding 2021 [2]) showed semaglutide 2.4 mg produced −14.9% total body weight at 68 weeks. These are the largest intentional weight-loss effects ever documented in a medication trial.
Large, sustained weight loss — from any cause — draws on both fat stores and lean tissue. The pre-specified body composition sub-study of SURMOUNT-1 (Look 2025 [3]) added serial DXA scans to 160 participants and found that, on the tirzepatide 10 mg arm at 72 weeks, fat mass fell by −33.9% and lean mass fell by −10.9%, with lean mass representing roughly 25% of the total weight lost. Crucially, the placebo arm showed nearly the same fat-to-lean ratio — meaning the lean-mass fraction tracks the size of the deficit, not the specific drug. The same proportion appears across decades of diet-only weight-loss studies (Cava 2017 [7]). The biology is straightforward: when you eat substantially less than you burn, the body draws on both fat and muscle protein to cover the shortfall. GLP-1 drugs make it easy to sustain a very large deficit; that deficit is the proximate cause of lean-mass loss. For the full mechanism, see our companion article on the biology of muscle loss on a GLP-1.
The peptides people try — and what the human evidence shows
A growing number of compounding clinics and wellness prescribers add one or more of the following peptides to GLP-1 protocols, marketing them as muscle-sparing agents. Here is what the published human evidence actually says about each, specifically for skeletal muscle preservation.
Sermorelin
Sermorelin is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). Its only FDA approval was as Geref for pediatric growth-hormone deficiency — a brand that has since been discontinued. A PubMed search for sermorelin and weight loss, obesity, fat loss, or muscle preservation returns no human randomized trial. The weight-loss and body-composition claims extrapolate from indirect GH/IGF-1 data or from the broader GHRH-analog literature. No published RCT has tested sermorelin against a placebo for muscle preservation in any population, let alone in GLP-1 therapy.
Ipamorelin
Ipamorelin is a selective growth-hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic. Its published human data consists of: a pharmacokinetic/pharmacodynamic modeling study in healthy volunteers showing it raises GH levels with fewer cortisol and prolactin side effects than earlier secretagogues (Gobburu 1999 [6]), and a clinical trial in post-bowel-resection patients where it reduced postoperative ileus. There is no published human RCT evaluating ipamorelin for lean-mass preservation during weight loss or during GLP-1 therapy. Ipamorelin is not FDA-approved for any indication.
CJC-1295
CJC-1295 is a long-acting GHRH analog designed for weekly or bi-weekly dosing. The pivotal human study (Teichman 2006 [5]) ran two randomized, placebo-controlled trials in healthy adults aged 21–61. After a single injection, mean GH rose 2- to 10-fold for 6 days or more and mean IGF-1 rose 1.5- to 3-fold for 9–11 days, in a dose-dependent way. The study measured GH and IGF-1 — not body composition, lean mass, or muscle performance. Raising GH and IGF-1 is a mechanism that could theoretically support muscle protein synthesis, but there is no published RCT in humans showing CJC-1295 preserves muscle mass during caloric restriction or GLP-1 therapy. CJC-1295 is not FDA-approved.
BPC-157
BPC-157 (body protective compound 157) is a synthetic peptide derived from a gastric protein. Its preclinical literature in rodents is extensive, spanning GI healing, tendon repair, and anti-inflammatory effects. The human evidence, however, consists of one published trial — a 1999 RCT in inflammatory bowel disease patients (not a body-composition study). There are no published human data on BPC-157 and skeletal muscle mass, lean mass preservation, or muscle outcomes during weight loss. BPC-157 is not FDA-approved. It was in FDA’s Category 2 of nominated bulk substances from September 2023 until April 22, 2026, and since October 28, 2026 a draft, non-binding HHS policy has said HHS does not intend to bring enforcement action against those 503A pharmacies that compound single-ingredient BPC-157 under ten conditions[9][10]. HHS is declining to enforce, not approving the drug, and the policy says nothing about muscle (see our HHS 503A peptide policy explainer and news report).
Tesamorelin
Tesamorelin (Egrifta SV / Egrifta WR) is the only peptide in this group that is actually FDA-approved — but its sole approved indication is the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The phase 3 pivotal trial (Falutz 2007 [4]) randomized 412 HIV-positive adults receiving antiretroviral therapy to tesamorelin or placebo for 26 weeks. Tesamorelin reduced trunk fat area by −18% versus +5% for placebo. The study measured visceral adipose tissue and metabolic markers — not skeletal muscle mass, and not in people taking a GLP-1 agonist. Lean mass was reported as roughly stable, but stability in an already-lean HIV lipodystrophy population receiving treatment for a fat redistribution syndrome is not the same as “muscle preservation during GLP-1-driven weight loss” in people with obesity. Tesamorelin is not approved for obesity, weight loss, or use alongside GLP-1 therapy.
Summary table: evidence by peptide
| Peptide | Claimed benefit | Best available human muscle evidence | FDA status |
|---|---|---|---|
| Sermorelin | GH stimulation → muscle preservation | No human RCT for muscle, lean mass, or body composition. GH/IGF-1 indirect data in older adults only. | Approved only for pediatric GH deficiency (brand discontinued); not approved for obesity or muscle |
| Ipamorelin | GH secretagogue → lean-mass protection | PK/PD in healthy volunteers (Gobburu 1999 [6]); one GI-motility trial. No body-composition endpoint in any trial. | Not FDA-approved for any indication |
| CJC-1295 | Sustained GH/IGF-1 elevation → muscle sparing | Phase 1 dose-finding: GH rises 2–10× and IGF-1 1.5–3× (Teichman 2006 [5]). No lean mass, body composition, or muscle outcomes measured. | Not FDA-approved for any indication |
| BPC-157 | Tissue repair and anti-catabolism | One published human GI trial; no body-composition data in any human study. | Not FDA-approved; since Oct 2026, single-ingredient 503A compounding under draft HHS enforcement discretion |
| Tesamorelin | GH stimulation → visceral fat loss and muscle sparing | Reduces visceral fat in HIV lipodystrophy (Falutz 2007 [4]). Lean mass roughly stable in that population. No RCT in obesity or on GLP-1s. | Approved — HIV-associated lipodystrophy only; not approved for obesity, weight loss, or use with GLP-1s |
The honest bottom line
No published human randomized trial has tested any of these peptides for muscle-mass preservation specifically during GLP-1 therapy. The evidence chain relies on mechanistic reasoning (raising GH/IGF-1 could support muscle protein synthesis) — which is plausible but untested at the level of human body-composition outcomes in this context. Tesamorelin has the strongest human data (Falutz 2007 [4]), but that data is for visceral fat redistribution in HIV lipodystrophy, not for lean-mass preservation in people losing weight on a GLP-1. Resistance training and adequate protein intake have replicated, mechanistically sound human RCT evidence for reducing lean-mass loss during caloric restriction ([7][8]). These are the evidence-based levers. Peptides are an adjunct hypothesis without the supporting trial data.
What is actually evidence-based: resistance training and protein
Two interventions have replicated human evidence for blunting lean-mass loss during caloric restriction, and both work in GLP-1 users.
Resistance training
Sardeli 2018 (Nutrients [8]) systematically reviewed and meta-analyzed six RCTs of resistance training during caloric restriction in obese older adults. Diet alone produced lean-mass loss averaging about 5% of baseline. Diet plus resistance training produced effectively no lean-mass loss. The training protocols used 2–3 sessions per week of compound movements (squat, press, row, deadlift pattern). The finding is mechanistically coherent: resistance exercise stimulates muscle protein synthesis through the mTOR pathway, directly counteracting the deficit-driven reduction in synthesis. See also the companion evidence review on GLP-1 muscle-loss prevention protocol for the practical implementation.
Adequate dietary protein
Cava 2017 (Advances in Nutrition [7]) reviewed the evidence for preserving healthy muscle during weight loss and found that high protein intake helps preserve lean body and muscle mass during weight loss, though it does not improve muscle strength. The authors recommend adequate (but not excessive) protein alongside a hypocaloric diet and resistance exercise [7]. GLP-1-driven appetite suppression frequently pushes protein intake down, which is why tracking protein — not total calories — is the priority for GLP-1 users concerned about lean mass. Animal-source proteins (whey, eggs, poultry, fish) provide the leucine density needed to maximally stimulate muscle protein synthesis per gram.
The evidence hierarchy is clear: resistance training + protein adequacy is the combination with replicated human RCT support. Peptides are an unvalidated add-on that costs money, involves injections, and carries regulatory and safety uncertainty — particularly for compounded preparations without FDA manufacturing oversight.
Should you discuss any of these peptides with your prescriber?
The honest framing: none of the peptides discussed here are FDA-approved for muscle preservation or for use alongside GLP-1 therapy. Tesamorelin is the one with real clinical-trial data, but it is approved only for HIV lipodystrophy and is typically not indicated for obesity or GLP-1 co-administration. If a clinic is offering you one of these peptides alongside your GLP-1, the appropriate questions are: “Is this FDA-approved for this purpose?” (answer: no, for all five), and “Is there a human RCT showing it preserves muscle during GLP-1 therapy?” (answer: no, for all five). The most important question — “Are you doing resistance training and eating enough protein?” — is the one most worth answering yes to. For a full index of peptides and what the human evidence says for each, see the peptide directory.
Practical protocol summary
- Resistance training: 2–3 sessions per week of compound lifts (squat, hinge, press, row). This is the single most evidence-supported intervention for preserving lean mass during caloric restriction [8].
- Protein: Aim for adequate, not excessive, protein. Track protein first, not total calories, since GLP-1 suppression makes it easy to under-eat protein [7].
- Peptides: No human RCT evidence of muscle preservation during GLP-1 therapy for any of the five peptides reviewed above. Not recommended as a primary intervention.
Our reviews
Strength-training apps we’ve reviewed
Workout apps and coaching for the exercise side of your plan. Each opens our full, independent review.
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). Tirzepatide 15 mg weekly produced mean body-weight loss of −20.9% vs −3.1% placebo at 72 weeks. N Engl J Med. 2022. PMID: 35658024.
- 2.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Semaglutide 2.4 mg weekly produced mean body-weight loss of −14.9% vs −2.4% placebo at 68 weeks. N Engl J Med. 2021. PMID: 33567185.
- 3.Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. DXA sub-study: lean mass ~25% of total weight lost on tirzepatide 10 mg at 72 weeks. Diabetes Obes Metab. 2025. PMID: 39996356.
- 4.Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. Phase 3 RCT in HIV lipodystrophy: tesamorelin reduced trunk fat area by ~18% vs placebo; study population and endpoint are not generalizable to muscle preservation on GLP-1 therapy. N Engl J Med. 2007. PMID: 18057338.
- 5.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Phase 1 dose-finding; no lean mass or body-composition endpoint. J Clin Endocrinol Metab. 2006. PMID: 16352683.
- 6.Gobburu JV, Agersø H, Jusko WJ, Agerso H. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. PK/PD study only; no body composition, lean mass, or muscle outcome. Pharm Res. 1999. PMID: 10496658.
- 7.Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Review: adequate (but not excessive) protein and resistance-type exercise help preserve muscle mass during weight loss. Adv Nutr. 2017. PMID: 28507015.
- 8.Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Meta-analysis: resistance training 2–3×/week abolished lean-mass loss during caloric restriction; diet-only lost ~5% lean mass. Nutrients. 2018. PMID: 29596307.
- 9.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and Appendix B). HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- 10.U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice; Docket No. HHS-OASH-2026-0496; FR Doc. 2026-22192. Federal Register. 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
Related research
Time-Restricted Eating With Lifting: Fat Loss or Muscle Loss?
Short trials suggest time-restricted eating alongside resistance training may trim a little fat without clear muscle loss. Here is what new meta-analyses show, why calories and protein may explain much of it, and where the evidence stops.
8 min read
Exercising on a GLP-1: Fueling & Low Energy (2026)
How to train, hit protein targets, and fix low energy on a GLP-1 when appetite is suppressed — evidence-based muscle-preservation and fueling guidance.
10 min read
How Long Does Sermorelin Take to Work?
Sermorelin raises GH within hours, but sleep and body-composition benefits take weeks to months — and no randomized trial has tested sermorelin in healthy adults for any of those outcomes.
9 min read
CJC-1295 (and the CJC-1295/Ipamorelin Stack) for Weight Loss: What the Evidence Shows
CJC-1295 is a long-acting GHRH analog, usually stacked with ipamorelin and marketed for fat loss. Neither is FDA-approved, no human trial shows the stack causes weight loss, and its development was halted at phase 2. An evidence review.
8 min read
Sermorelin for Weight Loss: What the Evidence Actually Shows
Sermorelin is a GHRH analog once sold as Geref for pediatric growth-hormone deficiency — never approved for weight loss, the brand is discontinued, and no human trial shows it causes weight loss. An evidence review.
8 min read
What Are Peptides for Weight Loss? Definition, Compounded Peptide Landscape + Evidence Review
Peptides for weight loss fall into three groups: FDA-approved peptide drugs (Wegovy, Zepbound, Saxenda), compounded versions of those drugs, and research peptides such as BPC-157, AOD-9604 and MOTS-c, none of which is FDA-approved or tested for weight loss in a phase 3 trial.
16 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →Pricing Compare
Get started →Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Read full review →Pricing Compare
Get started →Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →Pricing Compare
Get started →